PT3642242T - Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas - Google Patents
Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicasInfo
- Publication number
- PT3642242T PT3642242T PT188200117T PT18820011T PT3642242T PT 3642242 T PT3642242 T PT 3642242T PT 188200117 T PT188200117 T PT 188200117T PT 18820011 T PT18820011 T PT 18820011T PT 3642242 T PT3642242 T PT 3642242T
- Authority
- PT
- Portugal
- Prior art keywords
- hematologic malignancies
- dosing parameters
- targeting therapies
- therapies
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523182P | 2017-06-21 | 2017-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3642242T true PT3642242T (pt) | 2024-04-16 |
Family
ID=64735831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT188200117T PT3642242T (pt) | 2017-06-21 | 2018-06-21 | Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11141480B2 (https=) |
| EP (2) | EP3642242B1 (https=) |
| JP (2) | JP7312706B2 (https=) |
| KR (1) | KR102757177B1 (https=) |
| CN (2) | CN110831974B (https=) |
| AU (2) | AU2018290248B2 (https=) |
| CA (1) | CA3063099A1 (https=) |
| ES (1) | ES2976558T3 (https=) |
| PL (1) | PL3642242T3 (https=) |
| PT (1) | PT3642242T (https=) |
| SI (1) | SI3642242T1 (https=) |
| WO (1) | WO2018237168A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| WO2018237168A1 (en) * | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
| EA202190986A1 (ru) | 2018-11-26 | 2021-12-14 | Фоти Севен, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| ES2973832T3 (es) * | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| CN121243368A (zh) * | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| CN111905101B (zh) * | 2020-07-03 | 2022-09-23 | 中山大学 | 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| EP4291216A1 (en) * | 2021-02-09 | 2023-12-20 | University of Houston System | Oncolytic virus for systemic delivery and enhanced anti-tumor activities |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| AU2024225341A1 (en) | 2023-02-21 | 2025-09-04 | Osteal Therapeutics, Inc. | Methods of treating a localized infection with locally administered antibiotics |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2543819T3 (es) | 1998-11-09 | 2015-08-24 | Biogen Inc. | Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20 |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2582340T3 (es) * | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CA2771336C (en) * | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| NZ710695A (en) * | 2013-02-06 | 2020-05-29 | Inhibrx Inc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| CN103943054B (zh) | 2014-01-27 | 2016-07-13 | 上海中航光电子有限公司 | 栅极驱动电路、tft阵列基板、显示面板及显示装置 |
| KR102271434B1 (ko) | 2014-09-26 | 2021-07-01 | 엘지전자 주식회사 | 이동단말기 및 그 제어방법 |
| CN113528663A (zh) | 2014-12-10 | 2021-10-22 | 得克萨斯州大学系统董事会 | 使用基因组特异性探针的循环肿瘤和肿瘤干细胞检测 |
| WO2017053423A1 (en) * | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| WO2018237168A1 (en) | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
-
2018
- 2018-06-21 WO PCT/US2018/038798 patent/WO2018237168A1/en not_active Ceased
- 2018-06-21 CA CA3063099A patent/CA3063099A1/en active Pending
- 2018-06-21 CN CN201880040266.5A patent/CN110831974B/zh active Active
- 2018-06-21 CN CN202310844109.2A patent/CN117065013A/zh active Pending
- 2018-06-21 EP EP18820011.7A patent/EP3642242B1/en active Active
- 2018-06-21 PL PL18820011.7T patent/PL3642242T3/pl unknown
- 2018-06-21 JP JP2019570882A patent/JP7312706B2/ja active Active
- 2018-06-21 ES ES18820011T patent/ES2976558T3/es active Active
- 2018-06-21 AU AU2018290248A patent/AU2018290248B2/en active Active
- 2018-06-21 EP EP24155725.5A patent/EP4368206A3/en active Pending
- 2018-06-21 PT PT188200117T patent/PT3642242T/pt unknown
- 2018-06-21 SI SI201831075T patent/SI3642242T1/sl unknown
- 2018-06-21 KR KR1020197036583A patent/KR102757177B1/ko active Active
- 2018-06-21 US US16/619,387 patent/US11141480B2/en active Active
-
2021
- 2021-09-07 US US17/468,265 patent/US12274746B2/en active Active
-
2023
- 2023-04-18 JP JP2023067723A patent/JP2023083424A/ja active Pending
- 2023-05-05 US US18/143,978 patent/US12194093B2/en active Active
-
2024
- 2024-10-11 AU AU2024227248A patent/AU2024227248A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200147212A1 (en) | 2020-05-14 |
| PL3642242T3 (pl) | 2024-05-27 |
| CN110831974A (zh) | 2020-02-21 |
| EP3642242B1 (en) | 2024-02-07 |
| JP2023083424A (ja) | 2023-06-15 |
| AU2024227248A1 (en) | 2024-10-31 |
| US12194093B2 (en) | 2025-01-14 |
| EP4368206A2 (en) | 2024-05-15 |
| JP2020525435A (ja) | 2020-08-27 |
| US12274746B2 (en) | 2025-04-15 |
| ES2976558T3 (es) | 2024-08-05 |
| CA3063099A1 (en) | 2018-12-27 |
| US20210401979A1 (en) | 2021-12-30 |
| EP4368206A3 (en) | 2024-08-14 |
| CN110831974B (zh) | 2024-05-14 |
| AU2018290248A1 (en) | 2019-11-28 |
| WO2018237168A1 (en) | 2018-12-27 |
| US20230270852A1 (en) | 2023-08-31 |
| US11141480B2 (en) | 2021-10-12 |
| EP3642242A1 (en) | 2020-04-29 |
| SI3642242T1 (sl) | 2024-05-31 |
| JP7312706B2 (ja) | 2023-07-21 |
| AU2018290248B2 (en) | 2024-08-01 |
| KR102757177B1 (ko) | 2025-01-21 |
| EP3642242A4 (en) | 2021-06-23 |
| KR20200019619A (ko) | 2020-02-24 |
| CN117065013A (zh) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3642242T3 (pl) | Parametry dawkowania terapii celowanych cd47 w złośliwych nowotworach hematologicznych | |
| IL252442A0 (en) | Combined treatments | |
| IL247306A0 (en) | Specific antibody modification sites to create immunoconjugates | |
| IL243996A0 (en) | Immuno-oncolytic treatments | |
| PL3708516T3 (pl) | Opakowanie do papierosów | |
| IL247566A0 (en) | Routine payments to payment coordinators | |
| ZA201902009B (en) | Anti-folr1 immunocunjugate dosing regimens | |
| PL2905241T3 (pl) | Opakowanie do papierosów | |
| SI3347054T1 (sl) | Režimi doziranja konjugatov zdravil proti TF protitelesu | |
| IL249455A0 (en) | Complexes of mineral-amino acids with active substances | |
| SG11201700967RA (en) | Container with wrapper with removable portion | |
| IL254149A0 (en) | Innovative treatments for cancer | |
| EP3068702A4 (en) | Dosing container | |
| IL251870A0 (en) | Dosing regimens of buprenorphine | |
| SG11201507674UA (en) | Therapeutic uses for vegfr1 antibodies | |
| EP3098414A4 (en) | Muffler for construction machine | |
| PL2905242T3 (pl) | Opakowanie na papierosy | |
| GB201317293D0 (en) | Methods, materials and products for delivering biocides | |
| PL3268589T3 (pl) | Sposoby wypełniania tłumików materiałem włóknistym | |
| GB201506340D0 (en) | Container with wrapper | |
| GB201421869D0 (en) | SCR dosing system | |
| TWM476459U (en) | Fertilizer dispensing machine | |
| GB201510046D0 (en) | Chordal - automatic harmonizer for melody | |
| HUE038851T2 (hu) | Dohánytasak | |
| GB201415253D0 (en) | Tobacco pouch |